Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 4 5Phase 1/2 3Phase NA 2Phase 2 2Phase 1 1

Status

Completed 37Terminated 4Recruiting 4Unknown 2Not yet recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 387Breast Neoplasms 368Colorectal Neoplasms 242Stomach Neoplasms 221Carcinoma, Hepatocellular 155Lung Neoplasms 125Neoplasms 122Pancreatic Neoplasms 112Prostatic Neoplasms 101Rectal Neoplasms 98Neoplasm Metastasis 98Recurrence 94Ovarian Neoplasms 92Nasopharyngeal Carcinoma 89Esophageal Neoplasms 84Esophageal Squamous Cell Carcinoma 83Lymphoma, Large B-Cell, Diffuse 80Melanoma 78Lymphoma 72Small Cell Lung Carcinoma 71Sarcoma 71Leukemia, Myeloid, Acute 71Uterine Cervical Neoplasms 70Brain Neoplasms 70Squamous Cell Carcinoma of Head and Neck 67Multiple Myeloma 67Head and Neck Neoplasms 67Carcinoma, Renal Cell 65Triple Negative Breast Neoplasms 63Colonic Neoplasms 55

Interventions

Maxy G34 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Neutropenia × Clear all
NCT02544685 2019-01-17

FENSY

S&D Pharma SK s.r.o.

Phase 2 Unknown
120 enrolled
Classical hematology

Neoplasms, Neutropenia, Febrile Neutropenia

NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡